In Lung Adenocarcinoma, Low Expression of the Cell Surface Extracellular Nucleotidase CD39 is Related to Immune Infiltration and a Poor Prognosis

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2023 Jan 17

PMID 36647506

Authors

Lili Shao

Xiaoli Wang

Qiongzhu Yu

Jun Gong

Xiaodong Zhang

Yan Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Extracellular nucleotidase on the cell surface CD39 plays a crucial role in the tumor microenvironment in the immunosuppressive adenosine pathway. However, the association between CD39 and lung adenocarcinoma has rarely been recorded. This study aimed to explore the involvement of CD39 in the biological processes of lung cancer.

Methods: First, a prediction model was established by analyzing the expression of CD39 in lung adenocarcinoma and its relationships with clinical evidence of lung adenocarcinoma using The Cancer Genome Atlas (TCGA) and Tumor IMmune Estimation Resource (TIMER) databases. In the TCGA and TIMER databases, the relationship between CD39 and immune cells and the relationship with immune-related expressed genes were studied. Subsequently, using gene set enrichment analysis (GSEA), the potential mechanism of action was investigated.

Results: Lung adenocarcinoma patients with elevated CD39 expression had improved overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). CD39 expression was reduced in lung adenocarcinoma tumor tissue in the TCGA and TIMER databases. The nomogram's C-index was 0.688 (0.665-0.712), indicating some consistency in the prediction model. According to the TIMER and TCGA databases, CD39 expression was strongly connected with several immune cells invading and with immune checkpoint-related markers such as PDCD1, CD274, CTLA-4, and several functional T cells. GSEA revealed that CD39 influences the extracellular matrix, immunological microenvironment, programmed death 1 (PD-1) expression, glucose metabolism, PTEN stability, inflammatory response, and angiogenesis in lung cancer.

Conclusions: The current study's findings demonstrated that CD39 can be employed as a possible predictive biomarker for lung adenocarcinoma and may enhance the patients' poor prognosis by preventing the immunological escape of tumor cells from the lung adenocarcinoma tumor microenvironment.

References

Park C, Cho H, Choi Y, Oh I, Kim Y . A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. Cancer Res Treat. 2018; 51(2):777-787. PMC: 6473264. DOI: 10.4143/crt.2018.387. View

Li C, Hsia T, Yang S, Chao K, Tu C, Chen H . Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial. Integr Cancer Ther. 2022; 21:15347354221086663. PMC: 8943309. DOI: 10.1177/15347354221086663. View

Gallerano D, Ciminati S, Grimaldi A, Piconese S, Cammarata I, Focaccetti C . Genetically driven CD39 expression shapes human tumor-infiltrating CD8 T-cell functions. Int J Cancer. 2020; 147(9):2597-2610. DOI: 10.1002/ijc.33131. View

Brauneck F, Seubert E, Wellbrock J, Schulze Zur Wiesch J, Duan Y, Magnus T . Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML. Int J Mol Sci. 2021; 22(23). PMC: 8657570. DOI: 10.3390/ijms222312919. View

Hatfield S, Kjaergaard J, Lukashev D, Schreiber T, Belikoff B, Abbott R . Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med. 2015; 7(277):277ra30. PMC: 4641038. DOI: 10.1126/scitranslmed.aaa1260. View

Kim C, Kim K, Pyo K, Xin C, Hong M, Ahn B . Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol. 2019; 30(7):1104-1113. DOI: 10.1093/annonc/mdz123. View

Laumont C, Wouters M, Smazynski J, Gierc N, Chavez E, Chong L . Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer. Clin Cancer Res. 2021; 27(14):4089-4100. DOI: 10.1158/1078-0432.CCR-20-4394. View

Takenaka M, Gabriely G, Rothhammer V, Mascanfroni I, Wheeler M, Chao C . Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci. 2019; 22(5):729-740. PMC: 8052632. DOI: 10.1038/s41593-019-0370-y. View

Zheng Y, Li Y, Tang B, Zhao Q, Wang D, Liu Y . IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2020; 69(11):2371-2380. PMC: 11027717. DOI: 10.1007/s00262-020-02629-1. View

10.

Zheng M . Classification and Pathology of Lung Cancer. Surg Oncol Clin N Am. 2016; 25(3):447-68. DOI: 10.1016/j.soc.2016.02.003. View

11.

Zahran A, Rayan A, Zahran Z, Mohamed W, Mohamed D, Abdel-Rahim M . Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer. PLoS One. 2022; 17(1):e0262650. PMC: 8775239. DOI: 10.1371/journal.pone.0262650. View

12.

Li X, Moesta A, Xiao C, Nakamura K, Casey M, Zhang H . Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity. Cancer Discov. 2019; 9(12):1754-1773. PMC: 6891207. DOI: 10.1158/2159-8290.CD-19-0541. View

13.

You J, Yang G, Wu Y, Lu X, Huang S, Chen Q . Plasma tRF-1:29-Pro-AGG-1-M6 and tRF-55:76-Tyr-GTA-1-M2 as novel diagnostic biomarkers for lung adenocarcinoma. Front Oncol. 2022; 12:991451. PMC: 9530285. DOI: 10.3389/fonc.2022.991451. View

14.

Vijayan D, Young A, Teng M, Smyth M . Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017; 17(12):709-724. DOI: 10.1038/nrc.2017.86. View

15.

Wang J, He Z, Duan R . [Expression of ASPM in Lung Adenocarcinoma and Its Relationship with Development and Prognosis]. Zhongguo Fei Ai Za Zhi. 2020; 23(1):29-35. PMC: 7007395. DOI: 10.3779/j.issn.1009-3419.2020.01.05. View

16.

Yu Y, He J . Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis. Front Med. 2013; 7(2):157-71. DOI: 10.1007/s11684-013-0272-4. View

17.

Ran Z, Liu J, Wang F, Xin C, Shen X, Zeng S . [Analysis of Pulmonary Microbial Diversity in Patients with Advanced Lung Cancer Based on High-throughput Sequencing Technology]. Zhongguo Fei Ai Za Zhi. 2020; 23(12):1031-1038. PMC: 7786226. DOI: 10.3779/j.issn.1009-3419.2020.103.16. View

18.

Trautmann A . Extracellular ATP in the immune system: more than just a "danger signal". Sci Signal. 2009; 2(56):pe6. DOI: 10.1126/scisignal.256pe6. View

19.

Ding Y, Liu J . The signature lncRNAs associated with the lung adenocarcinoma patients prognosis. Math Biosci Eng. 2020; 17(2):1593-1603. DOI: 10.3934/mbe.2020083. View

20.

Gessi S, Varani K, Merighi S, Fogli E, Sacchetto V, Benini A . Adenosine and lymphocyte regulation. Purinergic Signal. 2008; 3(1-2):109-16. PMC: 2096755. DOI: 10.1007/s11302-006-9042-y. View